Active immunotherapeutics forum-Advance phase III active immunotherapy programs Just how well did the pre-clinical and early clinical trials translate? Case Studies: With the benefit of hindsight, what are the three biggest lessons learned from pre-clinical and early clinical trials? Meeting report from Barcelona, May 12 2011

The approval of Provenge (Dendreon) in 2010 signaled the dawn of a new era in the development of active immunotherapeutics. For cancer treatment, the approval of Provenge(R) demonstrates that the immune system can effectively be harnessed to combat cancer. The outlook for active immunotherapies looks bright in terms of promising new approaches and candidates, as well as novel adjuvants and treatment regimens for therapy development. Chairman: Dr. David L. Urdal, Dendreon Corporation Speakers: Dr. Carlos F. Santos, Accentia Biopharmaceuticals, Biovest International Dr. Martin Falk, Merck KGaA Dr. Valery R. Wagtmann, ALK Dr. Jill O'Donnell-Tormey, Cancer Research Institute Dr. Thomas Hinz, Paul-Ehrlich-Institute